ID   STAT1_HUMAN             Reviewed;         750 AA.
AC   P42224; A8K989; B2RCA0; D2KFR8; D3DPI7; Q53S88; Q53XW4; Q68D00; Q9UDL5;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   26-FEB-2020, entry version 237.
DE   RecName: Full=Signal transducer and activator of transcription 1-alpha/beta;
DE   AltName: Full=Transcription factor ISGF-3 components p91/p84;
GN   Name=STAT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA), AND PROTEIN SEQUENCE OF
RP   514-524; 654-660 AND 667-672.
RX   PubMed=1502203; DOI=10.1073/pnas.89.16.7836;
RA   Schindler C., Fu X.-Y., Improta T., Aebersold R., Darnell J.E. Jr.;
RT   "Proteins of transcription factor ISGF-3: one gene encodes the 91- and 84-
RT   kDa ISGF-3 proteins that are activated by interferon alpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:7836-7839(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA).
RA   Kristensen I., Veirum J.E., Moeller B.K., Christiansen M.;
RT   "Novel STAT1 alleles in a patient with impaired resistance to
RT   mycobacteria.";
RL   Submitted (NOV-2009) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7885841; DOI=10.1093/nar/23.3.459;
RA   Yan R., Qureshi S., Zhong Z., Wen Z., Darnell J.E. Jr.;
RT   "The genomic structure of the STAT genes: multiple exons in coincident
RT   sites in Stat1 and Stat2.";
RL   Nucleic Acids Res. 23:459-463(1995).
RN   [11]
RP   PHOSPHORYLATION IN RESPONSE TO IFN-ALPHA.
RX   PubMed=1638633; DOI=10.1016/0092-8674(92)90106-m;
RA   Fu X.Y.;
RT   "A transcription factor with SH2 and SH3 domains is directly activated by
RT   an interferon alpha-induced cytoplasmic protein tyrosine kinase(s).";
RL   Cell 70:323-335(1992).
RN   [12]
RP   PHOSPHORYLATION AT SER-727, AND MUTAGENESIS.
RX   PubMed=7543024; DOI=10.1016/0092-8674(95)90311-9;
RA   Wen Z., Zhong Z., Darnell J.E. Jr.;
RT   "Maximal activation of transcription by Stat1 and Stat3 requires both
RT   tyrosine and serine phosphorylation.";
RL   Cell 82:241-250(1995).
RN   [13]
RP   PHOSPHORYLATION AT TYR-701.
RX   PubMed=7657660; DOI=10.1074/jbc.270.35.20775;
RA   Quelle F.W., Thierfelder W., Witthuhn B.A., Tang B., Cohen S., Ihle J.N.;
RT   "Phosphorylation and activation of the DNA binding activity of purified
RT   Stat1 by the Janus protein-tyrosine kinases and the epidermal growth factor
RT   receptor.";
RL   J. Biol. Chem. 270:20775-20780(1995).
RN   [14]
RP   TYROSINE PHOSPHORYLATION, HETERODIMERIZATION, DNA-BINDING, AND MUTAGENESIS.
RX   PubMed=8605877; DOI=10.1002/j.1460-2075.1996.tb00445.x;
RA   Gupta S., Yan H., Wong L.H., Ralph S., Krolewski J., Schindler C.;
RT   "The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the
RT   transduction of IFN-alpha signals.";
RL   EMBO J. 15:1075-1084(1996).
RN   [15]
RP   INTERACTION WITH IFNAR1 AND IFNAR2, AND PHOSPHORYLATION.
RX   PubMed=9121453; DOI=10.1128/mcb.17.4.2048;
RA   Li X., Leung S., Kerr I.M., Stark G.R.;
RT   "Functional subdomains of STAT2 required for preassociation with the alpha
RT   interferon receptor and for signaling.";
RL   Mol. Cell. Biol. 17:2048-2056(1997).
RN   [16]
RP   INTERACTION WITH PIAS1, AND FUNCTION.
RC   TISSUE=B-cell;
RX   PubMed=9724754; DOI=10.1073/pnas.95.18.10626;
RA   Liu B., Liao J., Rao X., Kushner S.A., Chung C.D., Chang D.D., Shuai K.;
RT   "Inhibition of Stat1-mediated gene activation by PIAS1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10626-10631(1998).
RN   [17]
RP   INTERACTION WITH NMI, AND IDENTIFICATION IN A COMPLEX WITH NMI AND CREBBP.
RX   PubMed=9989503; DOI=10.1016/s0092-8674(00)80965-4;
RA   Zhu M.-H., John S., Berg M., Leonard W.J.;
RT   "Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-
RT   mediated signaling.";
RL   Cell 96:121-130(1999).
RN   [18]
RP   REVIEW.
RX   PubMed=10702714; DOI=10.1159/000053968;
RA   Cebulla C.M., Miller D.M., Sedmak D.D.;
RT   "Viral inhibition of interferon signal transduction.";
RL   Intervirology 42:325-330(1999).
RN   [19]
RP   INTERACTION WITH SENDAI VIRUS C PROTEIN.
RX   PubMed=11442634; DOI=10.1046/j.1365-2443.2001.00442.x;
RA   Takeuchi K., Komatsu T., Yokoo J., Kato A., Shioda T., Nagai Y., Gotoh B.;
RT   "Sendai virus C protein physically associates with Stat1.";
RL   Genes Cells 6:545-557(2001).
RN   [20]
RP   INTERACTION WITH PTK2/FAK1, AND PHOSPHORYLATION.
RX   PubMed=11278462; DOI=10.1074/jbc.m009063200;
RA   Xie B., Zhao J., Kitagawa M., Durbin J., Madri J.A., Guan J.L., Fu X.Y.;
RT   "Focal adhesion kinase activates Stat1 in integrin-mediated cell migration
RT   and adhesion.";
RL   J. Biol. Chem. 276:19512-19523(2001).
RN   [21]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2.
RX   PubMed=12138178; DOI=10.1128/mcb.22.16.5662-5668.2002;
RA   ten Hoeve J., de Jesus Ibarra-Sanchez M., Fu Y., Zhu W., Tremblay M.,
RA   David M., Shuai K.;
RT   "Identification of a nuclear Stat1 protein tyrosine phosphatase.";
RL   Mol. Cell. Biol. 22:5662-5668(2002).
RN   [22]
RP   SUMOYLATION AT LYS-703, FUNCTION, AND MUTAGENESIS OF LYS-703.
RX   PubMed=12855578; DOI=10.1182/blood-2002-12-3816;
RA   Ungureanu D., Vanhatupa S., Kotaja N., Yang J., Aittomaeki S., Jaenne O.A.,
RA   Palvimo J.J., Silvennoinen O.;
RT   "PIAS proteins promote SUMO-1 conjugation to STAT1.";
RL   Blood 102:3311-3313(2003).
RN   [23]
RP   SUMOYLATION AT LYS-703, FUNCTION, AND MUTAGENESIS OF LYS-110 AND LYS-703.
RX   PubMed=12764129; DOI=10.1074/jbc.m301344200;
RA   Rogers R.S., Horvath C.M., Matunis M.J.;
RT   "SUMO modification of STAT1 and its role in PIAS-mediated inhibition of
RT   gene activation.";
RL   J. Biol. Chem. 278:30091-30097(2003).
RN   [24]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [25]
RP   PHOSPHORYLATION AT SER-727, FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF SER-727.
RX   PubMed=15322115; DOI=10.1074/jbc.m407448200;
RA   DeVries T.A., Kalkofen R.L., Matassa A.A., Reyland M.E.;
RT   "Protein kinase Cdelta regulates apoptosis via activation of STAT1.";
RL   J. Biol. Chem. 279:45603-45612(2004).
RN   [26]
RP   INTERACTION WITH NIPAH V AND W PROTEINS.
RX   PubMed=15140960; DOI=10.1128/jvi.78.11.5633-5641.2004;
RA   Shaw M.L., Garcia-Sastre A., Palese P., Basler C.F.;
RT   "Nipah virus V and W proteins have a common STAT1-binding domain yet
RT   inhibit STAT1 activation from the cytoplasmic and nuclear compartments,
RT   respectively.";
RL   J. Virol. 78:5633-5641(2004).
RN   [27]
RP   ISGYLATION.
RX   PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
RA   Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
RA   Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
RT   "Proteomic identification of proteins conjugated to ISG15 in mouse and
RT   human cells.";
RL   Biochem. Biophys. Res. Commun. 336:496-506(2005).
RN   [28]
RP   INTERACTION WITH HEPATITIS C VIRUS CORE PROTEIN.
RX   PubMed=15825084; DOI=10.1053/j.gastro.2005.02.006;
RA   Lin W., Choe W.H., Hiasa Y., Kamegaya Y., Blackard J.T., Schmidt E.V.,
RA   Chung R.T.;
RT   "Hepatitis C virus expression suppresses interferon signaling by degrading
RT   STAT1.";
RL   Gastroenterology 128:1034-1041(2005).
RN   [29]
RP   PHOSPHORYLATION IN RESPONSE TO ACTIVATED FGFR3, AND PHOSPHORYLATION AT
RP   TYR-701.
RX   PubMed=17561467; DOI=10.1016/j.bone.2006.11.030;
RA   Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y.,
RA   Tanaka H.;
RT   "Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic
RT   dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via
RT   PLCgamma-activated STAT1.";
RL   Bone 41:273-281(2007).
RN   [30]
RP   PHOSPHORYLATION IN RESPONSE TO ACTIVATED FGFR1; FGFR2; FGFR3 AND FGFR4.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the
RT   Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [31]
RP   PHOSPHORYLATION AT SER-727, INTERACTION WITH PIAS1, SUMOYLATION, AND
RP   MUTAGENESIS OF TYR-701 AND SER-727.
RX   PubMed=17897103; DOI=10.1042/bj20070620;
RA   Vanhatupa S., Ungureanu D., Paakkunainen M., Silvennoinen O.;
RT   "MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1.";
RL   Biochem. J. 409:179-185(2008).
RN   [32]
RP   INTERACTION WITH ERBB4.
RX   PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006;
RA   Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G.;
RT   "System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation
RT   that are unusually selective in their recruitment properties.";
RL   Chem. Biol. 15:808-817(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [34]
RP   FUNCTION, AND PHOSPHORYLATION AT TYR-701 IN RESPONSE TO CONSTITUTIVELY
RP   ACTIVATED FGFR3.
RX   PubMed=19088846; DOI=10.1371/journal.pone.0003961;
RA   Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A.,
RA   Thompson L.M., Bryja V., Kozubik A., Wilcox W.R.;
RT   "Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal
RT   dysplasia undermines dominant role of STAT1 in FGFR3 signaling in
RT   cartilage.";
RL   PLoS ONE 3:E3961-E3961(2008).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [36]
RP   RETRACTED PAPER.
RX   PubMed=19136629; DOI=10.1101/gad.489409;
RA   Weber S., Maass F., Schuemann M., Krause E., Suske G., Bauer U.M.;
RT   "PRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling.";
RL   Genes Dev. 23:118-132(2009).
RN   [37]
RP   RETRACTION NOTICE OF PUBMED:19136629.
RX   PubMed=21724836;
RA   Weber S., Maass F., Schuemann M., Krause E., Suske G., Bauer U.M.;
RT   "Retraction. PRMT1-mediated arginine methylation of PIAS1 regulates STAT1
RT   signaling.";
RL   Genes Dev. 25:1451-1451(2011).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [41]
RP   PHOSPHORYLATION AT TYR-701 IN RESPONSE TO KIT SIGNALING, AND
RP   PHOSPHORYLATION AT SER-727.
RX   PubMed=21135090; DOI=10.1074/jbc.m110.182642;
RA   Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P., De Sepulveda P.;
RT   "Mechanisms of STAT protein activation by oncogenic KIT mutants in
RT   neoplastic mast cells.";
RL   J. Biol. Chem. 286:5956-5966(2011).
RN   [42]
RP   PHOSPHORYLATION AT TYR-701; SER-708 AND SER-727, AND MUTAGENESIS OF
RP   TYR-701; SER-708 AND SER-727.
RX   PubMed=22065572; DOI=10.1074/jbc.m111.285205;
RA   Perwitasari O., Cho H., Diamond M.S., Gale M. Jr.;
RT   "Inhibitor of kappaB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2
RT   proteins define novel innate immune effector pathway against West Nile
RT   virus infection.";
RL   J. Biol. Chem. 286:44412-44423(2011).
RN   [43]
RP   INTERACTION WITH EBOLAVIRUS PROTEIN VP24 (MICROBIAL INFECTION).
RX   PubMed=22383882; DOI=10.1371/journal.ppat.1002550;
RA   Zhang A.P., Bornholdt Z.A., Liu T., Abelson D.M., Lee D.E., Li S.,
RA   Woods V.L. Jr., Saphire E.O.;
RT   "The ebola virus interferon antagonist VP24 directly binds STAT1 and has a
RT   novel, pyramidal fold.";
RL   PLoS Pathog. 8:E1002550-E1002550(2012).
RN   [44]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [47]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-703, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [48]
RP   FUNCTION, INTERACTION WITH PARP9; DTX3L AND EP300, IDENTIFICATION IN A
RP   COMPLEX WITH PARP9 AND DTX3L, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   TYR-701 AND SER-727, AND MUTAGENESIS OF 656-ALA--ASN-658 AND TYR-701.
RX   PubMed=26479788; DOI=10.1038/ni.3279;
RA   Zhang Y., Mao D., Roswit W.T., Jin X., Patel A.C., Patel D.A., Agapov E.,
RA   Wang Z., Tidwell R.M., Atkinson J.J., Huang G., McCarthy R., Yu J.,
RA   Yun N.E., Paessler S., Lawson T.G., Omattage N.S., Brett T.J.,
RA   Holtzman M.J.;
RT   "PARP9-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C
RT   protease to enhance interferon signaling and control viral infection.";
RL   Nat. Immunol. 16:1215-1227(2015).
RN   [49]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-701, ADP-RIBOSYLATION AT
RP   GLU-657 AND GLU-705, AND MUTAGENESIS OF GLU-657 AND GLU-705.
RX   PubMed=27796300; DOI=10.1038/ncomms12849;
RA   Iwata H., Goettsch C., Sharma A., Ricchiuto P., Goh W.W., Halu A.,
RA   Yamada I., Yoshida H., Hara T., Wei M., Inoue N., Fukuda D., Mojcher A.,
RA   Mattson P.C., Barabasi A.L., Boothby M., Aikawa E., Singh S.A., Aikawa M.;
RT   "PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-
RT   ribosylation.";
RL   Nat. Commun. 7:12849-12849(2016).
RN   [50]
RP   METHYLATION AT LYS-114; LYS-175; LYS-296; LYS-366; LYS-525; LYS-637 AND
RP   LYS-665, PHOSPHORYLATION AT TYR-701, FUNCTION, SUBCELLULAR LOCATION,
RP   SUBUNIT, AND MUTAGENESIS OF LYS-114; LYS-175; LYS-296; LYS-366; LYS-525;
RP   636-LYS-LYS-637 AND LYS-665.
RX   PubMed=28753426; DOI=10.1016/j.cell.2017.06.042;
RA   Chen K., Liu J., Liu S., Xia M., Zhang X., Han D., Jiang Y., Wang C.,
RA   Cao X.;
RT   "Methyltransferase SETD2-mediated methylation of STAT1 is critical for
RT   interferon antiviral activity.";
RL   Cell 170:492-506(2017).
RN   [51]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-703, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [52]
RP   COMMENT ON ADP-RIBOSYLATION.
RX   PubMed=29858569; DOI=10.1038/s41467-018-04522-z;
RA   Begitt A., Cavey J., Droescher M., Vinkemeier U.;
RT   "On the role of STAT1 and STAT6 ADP-ribosylation in the regulation of
RT   macrophage activation.";
RL   Nat. Commun. 9:2144-2144(2018).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 136-710, AND COILED-COIL.
RX   PubMed=9630226; DOI=10.1016/s0092-8674(00)81443-9;
RA   Chen X., Vinkemeier U., Zhao Y., Jeruzalmi D., Darnell J.E. Jr.,
RA   Kuriyan J.;
RT   "Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to
RT   DNA.";
RL   Cell 93:827-839(1998).
RN   [54]
RP   VARIANT IMD31A SER-706.
RX   PubMed=11452125; DOI=10.1126/science.1061154;
RA   Dupuis S., Dargemont C., Fieschi C., Thomassin N., Rosenzweig S.,
RA   Harris J., Holland S.M., Schreiber R.D., Casanova J.-L.;
RT   "Impairment of mycobacterial but not viral immunity by a germline human
RT   STAT1 mutation.";
RL   Science 293:300-303(2001).
RN   [55]
RP   VARIANT IMD31B PRO-600.
RX   PubMed=12590259; DOI=10.1038/ng1097;
RA   Dupuis S., Jouanguy E., Al-Hajjar S., Fieschi C., Al-Mohsen I.Z.,
RA   Al-Jumaah S., Yang K., Chapgier A., Eidenschenk C., Eid P., Al-Ghonaium A.,
RA   Tufenkeji H., Frayha H., Al-Gazlan S., Al-Rayes H., Schreiber R.D.,
RA   Gresser I., Casanova J.L.;
RT   "Impaired response to interferon-alpha/beta and lethal viral disease in
RT   human STAT1 deficiency.";
RL   Nat. Genet. 33:388-391(2003).
RN   [56]
RP   VARIANTS IMD31A GLN-320 AND HIS-463, AND CHARACTERIZATION OF VARIANTS
RP   GLN-320; HIS-463 AND SER-706.
RX   PubMed=16934001; DOI=10.1371/journal.pgen.0020131;
RA   Chapgier A., Boisson-Dupuis S., Jouanguy E., Vogt G., Feinberg J.,
RA   Prochnicka-Chalufour A., Casrouge A., Yang K., Soudais C., Fieschi C.,
RA   Santos O.F., Bustamante J., Picard C., de Beaucoudrey L., Emile J.F.,
RA   Arkwright P.D., Schreiber R.D., Rolinck-Werninghaus C., Rosen-Wolff A.,
RA   Magdorf K., Roesler J., Casanova J.L.;
RT   "Novel STAT1 alleles in otherwise healthy patients with mycobacterial
RT   disease.";
RL   PLoS Genet. 2:E131-E131(2006).
RN   [57]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-491.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [58]
RP   VARIANT IMD31B ASN-201, AND CHARACTERIZATION OF VARIANT IMD31B ASN-201.
RX   PubMed=20841510; DOI=10.1182/blood-2010-04-280586;
RA   Kong X.F., Ciancanelli M., Al-Hajjar S., Alsina L., Zumwalt T.,
RA   Bustamante J., Feinberg J., Audry M., Prando C., Bryant V., Kreins A.,
RA   Bogunovic D., Halwani R., Zhang X.X., Abel L., Chaussabel D., Al-Muhsen S.,
RA   Casanova J.L., Boisson-Dupuis S.;
RT   "A novel form of human STAT1 deficiency impairing early but not late
RT   responses to interferons.";
RL   Blood 116:5895-5906(2010).
RN   [59]
RP   VARIANTS IMD31C GLY-165; HIS-165; ASN-170; ARG-174; ILE-202; VAL-202;
RP   VAL-267; PRO-271; GLN-274; TRP-274; ILE-286 AND ALA-288, AND
RP   CHARACTERIZATION OF VARIANTS IMD31C GLY-165 AND GLN-274.
RX   PubMed=21727188; DOI=10.1084/jem.20110958;
RA   Liu L., Okada S., Kong X.F., Kreins A.Y., Cypowyj S., Abhyankar A.,
RA   Toubiana J., Itan Y., Audry M., Nitschke P., Masson C., Toth B., Flatot J.,
RA   Migaud M., Chrabieh M., Kochetkov T., Bolze A., Borghesi A., Toulon A.,
RA   Hiller J., Eyerich S., Eyerich K., Gulacsy V., Chernyshova L.,
RA   Chernyshov V., Bondarenko A., Maria Cortes Grimaldo R., Blancas-Galicia L.,
RA   Madrigal Beas I.M., Roesler J., Magdorf K., Engelhard D., Thumerelle C.,
RA   Burgel P.R., Hoernes M., Drexel B., Seger R., Kusuma T., Jansson A.F.,
RA   Sawalle-Belohradsky J., Belohradsky B., Jouanguy E., Bustamante J., Bue M.,
RA   Karin N., Wildbaum G., Bodemer C., Lortholary O., Fischer A., Blanche S.,
RA   Al-Muhsen S., Reichenbach J., Kobayashi M., Rosales F.E., Lozano C.T.,
RA   Kilic S.S., Oleastro M., Etzioni A., Traidl-Hoffmann C., Renner E.D.,
RA   Abel L., Picard C., Marodi L., Boisson-Dupuis S., Puel A., Casanova J.L.;
RT   "Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie
RT   chronic mucocutaneous candidiasis.";
RL   J. Exp. Med. 208:1635-1648(2011).
RN   [60]
RP   VARIANTS IMD31C VAL-267 AND TRP-274.
RX   PubMed=21714643; DOI=10.1056/nejmoa1100102;
RA   van de Veerdonk F.L., Plantinga T.S., Hoischen A., Smeekens S.P.,
RA   Joosten L.A., Gilissen C., Arts P., Rosentul D.C., Carmichael A.J.,
RA   Smits-van der Graaf C.A., Kullberg B.J., van der Meer J.W., Lilic D.,
RA   Veltman J.A., Netea M.G.;
RT   "STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.";
RL   N. Engl. J. Med. 365:54-61(2011).
RN   [61]
RP   VARIANTS IMD31A GLU-637 AND ARG-673, AND CHARACTERIZATION OF VARIANTS
RP   IMD31A GLU-637 AND ARG-673.
RX   PubMed=22573496; DOI=10.1002/humu.22113;
RA   Tsumura M., Okada S., Sakai H., Yasunaga S., Ohtsubo M., Murata T.,
RA   Obata H., Yasumi T., Kong X.F., Abhyankar A., Heike T., Nakahata T.,
RA   Nishikomori R., Al-Muhsen S., Boisson-Dupuis S., Casanova J.L.,
RA   Alzahrani M., Shehri M.A., Elghazali G., Takihara Y., Kobayashi M.;
RT   "Dominant-negative STAT1 SH2 domain mutations in unrelated patients with
RT   Mendelian susceptibility to mycobacterial disease.";
RL   Hum. Mutat. 33:1377-1387(2012).
RN   [62]
RP   VARIANTS IMD31C GLY-165; LYS-179; GLN-274; TRP-274; ARG-285 AND MET-385,
RP   CHARACTERIZATION OF VARIANTS IMD31C LYS-179; GLN-274; TRP-274; ARG-285 AND
RP   MET-385, AND CHARACTERIZATION OF VARIANT IMD31B CYS-701.
RX   PubMed=23709754; DOI=10.1136/jmedgenet-2013-101570;
RA   Soltesz B., Toth B., Shabashova N., Bondarenko A., Okada S., Cypowyj S.,
RA   Abhyankar A., Csorba G., Tasko S., Sarkadi A.K., Mehes L., Rozsival P.,
RA   Neumann D., Chernyshova L., Tulassay Z., Puel A., Casanova J.L., Sediva A.,
RA   Litzman J., Marodi L.;
RT   "New and recurrent gain-of-function STAT1 mutations in patients with
RT   chronic mucocutaneous candidiasis from Eastern and Central Europe.";
RL   J. Med. Genet. 50:567-578(2013).
RN   [63]
RP   VARIANTS IMD31C GLU-278 AND ASP-384, AND CHARACTERIZATION OF VARIANTS
RP   IMD31C GLU-278; ASP-384 AND MET-385.
RX   PubMed=25288569; DOI=10.4049/jimmunol.1401467;
RA   Yamazaki Y., Yamada M., Kawai T., Morio T., Onodera M., Ueki M.,
RA   Watanabe N., Takada H., Takezaki S., Chida N., Kobayashi I., Ariga T.;
RT   "Two novel gain-of-function mutations of STAT1 responsible for chronic
RT   mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22,
RT   and the presence of anti-IL-17F autoantibody.";
RL   J. Immunol. 193:4880-4887(2014).
RN   [64]
RP   VARIANT IMD31C ASN-298, AND CHARACTERIZATION OF VARIANT IMD31C ASN-298.
RX   PubMed=26514428; DOI=10.1016/j.molimm.2015.09.014;
RA   Martinez-Martinez L., Martinez-Saavedra M.T., Fuentes-Prior P.,
RA   Barnadas M., Rubiales M.V., Noda J., Badell I., Rodriguez-Gallego C.,
RA   Calle-Martin O.L.;
RT   "A novel gain-of-function STAT1 mutation resulting in basal phosphorylation
RT   of STAT1 and increased distal IFN-gamma-mediated responses in chronic
RT   mucocutaneous candidiasis.";
RL   Mol. Immunol. 68:597-605(2015).
CC   -!- FUNCTION: Signal transducer and transcription activator that mediates
CC       cellular responses to interferons (IFNs), cytokine KITLG/SCF and other
CC       cytokines and other growth factors. Following type I IFN (IFN-alpha and
CC       IFN-beta) binding to cell surface receptors, signaling via protein
CC       kinases leads to activation of Jak kinases (TYK2 and JAK1) and to
CC       tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs
CC       dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3
CC       transcription factor, that enters the nucleus (PubMed:28753426). ISGF3
CC       binds to the IFN stimulated response element (ISRE) to activate the
CC       transcription of IFN-stimulated genes (ISG), which drive the cell in an
CC       antiviral state. In response to type II IFN (IFN-gamma), STAT1 is
CC       tyrosine- and serine-phosphorylated (PubMed:26479788). It then forms a
CC       homodimer termed IFN-gamma-activated factor (GAF), migrates into the
CC       nucleus and binds to the IFN gamma activated sequence (GAS) to drive
CC       the expression of the target genes, inducing a cellular antiviral
CC       state. Becomes activated in response to KITLG/SCF and KIT signaling.
CC       May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and
CC       FGFR4. {ECO:0000269|PubMed:12764129, ECO:0000269|PubMed:12855578,
CC       ECO:0000269|PubMed:15322115, ECO:0000269|PubMed:19088846,
CC       ECO:0000269|PubMed:26479788, ECO:0000269|PubMed:28753426,
CC       ECO:0000269|PubMed:9724754}.
CC   -!- SUBUNIT: Isoform alpha homodimerizes upon IFN-gamma induced
CC       phosphorylation (PubMed:8605877, PubMed:28753426). Heterodimer with
CC       STAT2 upon IFN-alpha/beta induced phosphorylation (PubMed:8605877). The
CC       heterodimer STAT1:STAT2 forms the interferon-stimulated gene factor 3
CC       complex (ISGF3) with IRF9 (By similarity). Interacts (phosphorylated at
CC       Ser-727) with PIAS1; the interaction results in release of STAT1 from
CC       its target gene (PubMed:9724754, PubMed:17897103). Interacts with
CC       IFNAR1; the interaction requires the phosphorylation of IFNAR1 at 'Tyr-
CC       466' (PubMed:9121453). Interacts with IFNAR2 (PubMed:9121453). Found in
CC       a complex with NMI and CREBBP/CBP (PubMed:9989503). Interacts with NMI
CC       which is required for CREBBP/CBP recruitment to the complex
CC       (PubMed:9989503). Interacts with PTK2/FAK1 (PubMed:11278462). Interacts
CC       with SRC (By similarity). Interacts with ERBB4 (phosphorylated)
CC       (PubMed:18721752). Interacts with PARP9 and DTX3L independently of IFN-
CC       beta or IFN-gamma-mediated STAT1 'Tyr-701' phosphorylation
CC       (PubMed:26479788). Interacts with histone acetyltransferase EP300/p300
CC       in response to INF-gamma stimulation (PubMed:26479788). Interacts with
CC       OTOP1 (By similarity). {ECO:0000250|UniProtKB:P42225,
CC       ECO:0000269|PubMed:11278462, ECO:0000269|PubMed:17897103,
CC       ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:26479788,
CC       ECO:0000269|PubMed:28753426, ECO:0000269|PubMed:8605877,
CC       ECO:0000269|PubMed:9121453, ECO:0000269|PubMed:9724754,
CC       ECO:0000269|PubMed:9989503}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Sendai virus C', C, Y1
CC       and Y2 proteins, preventing activation of ISRE and GAS promoter.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Nipah virus P, V and W
CC       proteins preventing activation of ISRE and GAS promoter.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Rabies virus
CC       phosphoprotein preventing activation of ISRE and GAS promoter.
CC       {ECO:0000269|PubMed:11442634, ECO:0000269|PubMed:15140960}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HCV core protein; the
CC       interaction results in STAT1 degradation.
CC       {ECO:0000269|PubMed:15825084}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with ebolavirus protein VP24.
CC       {ECO:0000269|PubMed:22383882}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-1057697, EBI-1057697;
CC       P03255-1:- (xeno); NbExp=2; IntAct=EBI-1057697, EBI-6692439;
CC       P03255-2:- (xeno); NbExp=2; IntAct=EBI-1057697, EBI-6859460;
CC       P06498:- (xeno); NbExp=2; IntAct=EBI-15711971, EBI-16085959;
CC       P26664:- (xeno); NbExp=5; IntAct=EBI-1057697, EBI-6941357;
CC       P27958:- (xeno); NbExp=4; IntAct=EBI-1057697, EBI-8753518;
CC       Q16531:DDB1; NbExp=2; IntAct=EBI-1057697, EBI-350322;
CC       O95786:DDX58; NbExp=4; IntAct=EBI-1057697, EBI-995350;
CC       Q01094:E2F1; NbExp=2; IntAct=EBI-1057697, EBI-448924;
CC       P00533:EGFR; NbExp=6; IntAct=EBI-1057697, EBI-297353;
CC       Q8N9N8:EIF1AD; NbExp=4; IntAct=EBI-1057697, EBI-750700;
CC       P04626:ERBB2; NbExp=3; IntAct=EBI-1057697, EBI-641062;
CC       P01100:FOS; NbExp=6; IntAct=EBI-1057697, EBI-852851;
CC       P07239:H1L (xeno); NbExp=2; IntAct=EBI-1057697, EBI-7789600;
CC       P17181:IFNAR1; NbExp=2; IntAct=EBI-1057697, EBI-1547250;
CC       P48551:IFNAR2; NbExp=2; IntAct=EBI-1057697, EBI-958408;
CC       P15260:IFNGR1; NbExp=4; IntAct=EBI-1057697, EBI-1030755;
CC       Q9Y4C1:KDM3A; NbExp=8; IntAct=EBI-15711971, EBI-2515339;
CC       Q7Z434:MAVS; NbExp=3; IntAct=EBI-1057697, EBI-995373;
CC       Q01804:OTUD4; NbExp=3; IntAct=EBI-1057697, EBI-1054396;
CC       P19793:RXRA; NbExp=2; IntAct=EBI-1057697, EBI-78598;
CC       P52630:STAT2; NbExp=15; IntAct=EBI-1057697, EBI-1546963;
CC       P40763:STAT3; NbExp=4; IntAct=EBI-1057697, EBI-518675;
CC       Q4VW77:UL47 (xeno); NbExp=2; IntAct=EBI-1057697, EBI-11499224;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15322115,
CC       ECO:0000269|PubMed:26479788, ECO:0000269|PubMed:27796300,
CC       ECO:0000269|PubMed:28753426}. Nucleus {ECO:0000269|PubMed:15322115,
CC       ECO:0000269|PubMed:26479788, ECO:0000269|PubMed:28753426}.
CC       Note=Translocated into the nucleus upon tyrosine phosphorylation and
CC       dimerization, in response to IFN-gamma and signaling by activated
CC       FGFR1, FGFR2, FGFR3 or FGFR4 (PubMed:15322115). Monomethylation at Lys-
CC       525 is required for phosphorylation at Tyr-701 and translocation into
CC       the nucleus (PubMed:28753426). Translocates into the nucleus in
CC       response to interferon-beta stimulation (PubMed:26479788).
CC       {ECO:0000269|PubMed:15322115, ECO:0000269|PubMed:26479788,
CC       ECO:0000269|PubMed:28753426}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Alpha; Synonyms=p91;
CC         IsoId=P42224-1; Sequence=Displayed;
CC       Name=Beta; Synonyms=p84;
CC         IsoId=P42224-2; Sequence=VSP_006282;
CC   -!- PTM: Phosphorylated on tyrosine and serine residues in response to a
CC       variety of cytokines/growth hormones including IFN-alpha, IFN-gamma,
CC       PDGF and EGF. Activated KIT promotes phosphorylation on tyrosine
CC       residues and subsequent translocation to the nucleus. Upon EGF
CC       stimulation, phosphorylation on Tyr-701 (lacking in beta form) by JAK1,
CC       JAK2 or TYK2 promotes dimerization and subsequent translocation to the
CC       nucleus. Growth hormone (GH) activates STAT1 signaling only via JAK2.
CC       Tyrosine phosphorylated in response to constitutively activated FGFR1,
CC       FGFR2, FGFR3 and FGFR4. Phosphorylation on Ser-727 by several kinases
CC       including MAPK14, ERK1/2 and CAMKII on IFN-gamma stimulation, regulates
CC       STAT1 transcriptional activity. Phosphorylation on Ser-727 promotes
CC       sumoylation though increasing interaction with PIAS. Phosphorylation on
CC       Ser-727 by PRKCD induces apoptosis in response to DNA-damaging agents.
CC       Phosphorylated on tyrosine residues when PTK2/FAK1 is activated; most
CC       likely this is catalyzed by a SRC family kinase. Dephosphorylation on
CC       tyrosine residues by PTPN2 negatively regulates interferon-mediated
CC       signaling. Upon viral infection or IFN induction, phosphorylation on
CC       Ser-708 occurs much later than phosphorylation on Tyr-701 and is
CC       required for the binding of ISGF3 on the ISREs of a subset of IFN-
CC       stimulated genes IKBKE-dependent. Phosphorylation at Tyr-701 and Ser-
CC       708 are mutually exclusive, phosphorylation at Ser-708 requires
CC       previous dephosphorylation of Tyr-701. {ECO:0000269|PubMed:15322115,
CC       ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:17897103,
CC       ECO:0000269|PubMed:19088846, ECO:0000269|PubMed:21135090,
CC       ECO:0000269|PubMed:22065572, ECO:0000269|PubMed:26479788,
CC       ECO:0000269|PubMed:28753426, ECO:0000269|PubMed:7543024,
CC       ECO:0000269|PubMed:7657660}.
CC   -!- PTM: Sumoylated with SUMO1, SUMO2 and SUMO3. Sumoylation is enhanced by
CC       IFN-gamma-induced phosphorylation on Ser-727, and by interaction with
CC       PIAS proteins. Enhances the transactivation activity.
CC       {ECO:0000269|PubMed:15322115, ECO:0000269|PubMed:17897103,
CC       ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:22065572,
CC       ECO:0000269|PubMed:7543024}.
CC   -!- PTM: ISGylated. {ECO:0000269|PubMed:16139798}.
CC   -!- PTM: Mono-ADP-ribosylated at Glu-657 and Glu-705 by PARP14; ADP-
CC       ribosylation prevents phosphorylation at Tyr-701 (PubMed:27796300).
CC       However, the role of ADP-ribosylation in the prevention of
CC       phosphorylation has been called into question and the lack of
CC       phosphorylation may be due to sumoylation of Lys-703 (PubMed:29858569).
CC       {ECO:0000269|PubMed:27796300, ECO:0000305|PubMed:29858569}.
CC   -!- PTM: Monomethylated at Lys-525 by SETD2; monomethylation is necessary
CC       for phosphorylation at Tyr-701, translocation into the nucleus and
CC       activation of the antiviral defense. {ECO:0000269|PubMed:28753426}.
CC   -!- DISEASE: Immunodeficiency 31B (IMD31B) [MIM:613796]: A disorder
CC       characterized by susceptibility to severe mycobacterial and viral
CC       infections. Affected individuals can develop disseminated infections
CC       and die of viral illness. {ECO:0000269|PubMed:12590259,
CC       ECO:0000269|PubMed:20841510, ECO:0000269|PubMed:23709754}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Immunodeficiency 31A (IMD31A) [MIM:614892]: A form of
CC       Mendelian susceptibility to mycobacterial disease, a rare condition
CC       caused by impairment of interferon-gamma mediated immunity. It is
CC       characterized by predisposition to illness caused by moderately
CC       virulent mycobacterial species, such as Bacillus Calmette-Guerin (BCG)
CC       vaccine, environmental non-tuberculous mycobacteria, and by the more
CC       virulent Mycobacterium tuberculosis. Other microorganisms rarely cause
CC       severe clinical disease in individuals with susceptibility to
CC       mycobacterial infections, with the exception of Salmonella which
CC       infects less than 50% of these individuals. Clinical outcome severity
CC       depends on the degree of impairment of interferon-gamma mediated
CC       immunity. Some patients die of overwhelming mycobacterial disease with
CC       lepromatous-like lesions in early childhood, whereas others develop,
CC       later in life, disseminated but curable infections with tuberculoid
CC       granulomas. IMD31A has low penetrance, and affected individuals have
CC       relatively mild disease and good prognosis. IMD31A confers a
CC       predisposition to mycobacterial infections only, with no increased
CC       susceptibility to viral infections. {ECO:0000269|PubMed:11452125,
CC       ECO:0000269|PubMed:16934001, ECO:0000269|PubMed:22573496}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Immunodeficiency 31C (IMD31C) [MIM:614162]: A primary
CC       immunodeficiency disorder with altered immune responses and impaired
CC       clearance of fungal infections, selective against Candida. It is
CC       characterized by persistent and/or recurrent infections of the skin,
CC       nails and mucous membranes caused by organisms of the genus Candida,
CC       mainly Candida albicans. {ECO:0000269|PubMed:21714643,
CC       ECO:0000269|PubMed:21727188, ECO:0000269|PubMed:23709754,
CC       ECO:0000269|PubMed:25288569, ECO:0000269|PubMed:26514428}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry. STAT1 mutations in patients with autosomal dominant candidiasis
CC       lead to defective responses of type 1 and type 17 helper T-cells,
CC       characterized by reduced production of interferon-alpha, interleukin-
CC       17, and interleukin-22. These cytokines are crucial for the antifungal
CC       defense of skin and mucosa (PubMed:21714643).
CC       {ECO:0000269|PubMed:21714643}.
CC   -!- SIMILARITY: Belongs to the transcription factor STAT family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Has been shown to be mono-ADP-ribosylated at Glu-657 and Glu-
CC       705 by PARP14 which prevents phosphorylation at Tyr-701
CC       (PubMed:27796300). However, the role of ADP-ribosylation in the
CC       prevention of phosphorylation has been called into question
CC       (PubMed:29858569). It has been suggested that the lack of
CC       phosphorylation may be due to sumoylation of Lys-703 (PubMed:29858569).
CC       {ECO:0000269|PubMed:27796300, ECO:0000305|PubMed:29858569}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/stat1/";
CC   -!- WEB RESOURCE: Name=STAT1base; Note=STAT1 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/STAT1base/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=STAT1 entry;
CC       URL="https://en.wikipedia.org/wiki/STAT1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M97935; AAB64012.1; -; mRNA.
DR   EMBL; M97936; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; GU211347; ADA59516.1; -; mRNA.
DR   EMBL; AY865620; AAW56072.1; -; Genomic_DNA.
DR   EMBL; AK292604; BAF85293.1; -; mRNA.
DR   EMBL; AK315002; BAG37497.1; -; mRNA.
DR   EMBL; CR749636; CAH18430.1; -; mRNA.
DR   EMBL; BT007241; AAP35905.1; -; mRNA.
DR   EMBL; AC067945; AAY24183.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX10850.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX10851.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX10852.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX10855.1; -; Genomic_DNA.
DR   EMBL; BC002704; AAH02704.1; -; mRNA.
DR   EMBL; U18662; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U18663; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U18664; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U18665; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U18666; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U18667; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U18668; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U18669; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U18670; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS2309.1; -. [P42224-1]
DR   CCDS; CCDS42793.1; -. [P42224-2]
DR   PIR; A46159; A46159.
DR   RefSeq; NP_009330.1; NM_007315.3. [P42224-1]
DR   RefSeq; NP_644671.1; NM_139266.2. [P42224-2]
DR   RefSeq; XP_006712781.1; XM_006712718.1. [P42224-1]
DR   PDB; 1BF5; X-ray; 2.90 A; A=136-710.
DR   PDB; 1YVL; X-ray; 3.00 A; A/B=1-683.
DR   PDB; 2KA6; NMR; -; B=710-750.
DR   PDB; 3WWT; X-ray; 2.00 A; A=1-126.
DR   PDBsum; 1BF5; -.
DR   PDBsum; 1YVL; -.
DR   PDBsum; 2KA6; -.
DR   PDBsum; 3WWT; -.
DR   SMR; P42224; -.
DR   BioGrid; 112649; 187.
DR   CORUM; P42224; -.
DR   DIP; DIP-46140N; -.
DR   IntAct; P42224; 103.
DR   MINT; P42224; -.
DR   STRING; 9606.ENSP00000354394; -.
DR   BindingDB; P42224; -.
DR   ChEMBL; CHEMBL6101; -.
DR   CarbonylDB; P42224; -.
DR   iPTMnet; P42224; -.
DR   PhosphoSitePlus; P42224; -.
DR   SwissPalm; P42224; -.
DR   BioMuta; STAT1; -.
DR   DMDM; 2507413; -.
DR   CPTAC; CPTAC-1272; -.
DR   EPD; P42224; -.
DR   jPOST; P42224; -.
DR   MassIVE; P42224; -.
DR   MaxQB; P42224; -.
DR   PaxDb; P42224; -.
DR   PeptideAtlas; P42224; -.
DR   PRIDE; P42224; -.
DR   ProteomicsDB; 55491; -. [P42224-1]
DR   ProteomicsDB; 55492; -. [P42224-2]
DR   DNASU; 6772; -.
DR   Ensembl; ENST00000361099; ENSP00000354394; ENSG00000115415. [P42224-1]
DR   Ensembl; ENST00000392322; ENSP00000376136; ENSG00000115415. [P42224-2]
DR   Ensembl; ENST00000409465; ENSP00000386244; ENSG00000115415. [P42224-1]
DR   GeneID; 6772; -.
DR   KEGG; hsa:6772; -.
DR   UCSC; uc002usj.3; human. [P42224-1]
DR   CTD; 6772; -.
DR   DisGeNET; 6772; -.
DR   GeneCards; STAT1; -.
DR   HGNC; HGNC:11362; STAT1.
DR   HPA; CAB004049; -.
DR   HPA; HPA000931; -.
DR   HPA; HPA000982; -.
DR   MalaCards; STAT1; -.
DR   MIM; 600555; gene.
DR   MIM; 613796; phenotype.
DR   MIM; 614162; phenotype.
DR   MIM; 614892; phenotype.
DR   neXtProt; NX_P42224; -.
DR   OpenTargets; ENSG00000115415; -.
DR   Orphanet; 391487; Autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome.
DR   Orphanet; 319595; Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency.
DR   Orphanet; 391311; Susceptibility to viral and mycobacterial infections.
DR   PharmGKB; PA36183; -.
DR   eggNOG; KOG3667; Eukaryota.
DR   eggNOG; ENOG410XPN8; LUCA.
DR   GeneTree; ENSGT00950000182688; -.
DR   HOGENOM; CLU_014189_3_0_1; -.
DR   InParanoid; P42224; -.
DR   KO; K11220; -.
DR   OMA; NEPQFHS; -.
DR   OrthoDB; 327469at2759; -.
DR   PhylomeDB; P42224; -.
DR   TreeFam; TF318648; -.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling. [P42224-1]
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT. [P42224-1]
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-877300; Interferon gamma signaling. [P42224-1]
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling. [P42224-1]
DR   Reactome; R-HSA-8854691; Interleukin-20 family signaling.
DR   Reactome; R-HSA-8939902; Regulation of RUNX2 expression and activity.
DR   Reactome; R-HSA-8984722; Interleukin-35 Signalling.
DR   Reactome; R-HSA-8985947; Interleukin-9 signaling.
DR   Reactome; R-HSA-9013508; NOTCH3 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-9020956; Interleukin-27 signaling.
DR   Reactome; R-HSA-9020958; Interleukin-21 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-912694; Regulation of IFNA signaling.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   SignaLink; P42224; -.
DR   SIGNOR; P42224; -.
DR   ChiTaRS; STAT1; human.
DR   EvolutionaryTrace; P42224; -.
DR   GeneWiki; STAT1; -.
DR   GenomeRNAi; 6772; -.
DR   Pharos; P42224; Tchem.
DR   PRO; PR:P42224; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P42224; protein.
DR   Bgee; ENSG00000115415; Expressed in epithelium of bronchus and 233 other tissues.
DR   ExpressionAtlas; P42224; baseline and differential.
DR   Genevisible; P42224; HS.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:AgBase.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0031730; F:CCR5 chemokine receptor binding; IEA:Ensembl.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0035257; F:nuclear hormone receptor binding; IPI:UniProtKB.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IEA:Ensembl.
DR   GO; GO:0070491; F:repressing transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0005164; F:tumor necrosis factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0044389; F:ubiquitin-like protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0008015; P:blood circulation; ISS:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0035458; P:cellular response to interferon-beta; IMP:BHF-UCL.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IDA:UniProtKB.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0006952; P:defense response; IBA:GO_Central.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0038114; P:interleukin-21-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070106; P:interleukin-27-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070757; P:interleukin-35-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038113; P:interleukin-9-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0010742; P:macrophage derived foam cell differentiation; IDA:UniProtKB.
DR   GO; GO:0072162; P:metanephric mesenchymal cell differentiation; ISS:UniProtKB.
DR   GO; GO:0072136; P:metanephric mesenchymal cell proliferation involved in metanephros development; ISS:UniProtKB.
DR   GO; GO:0046725; P:negative regulation by virus of viral protein levels in host cell; IMP:AgBase.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0003340; P:negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis; ISS:UniProtKB.
DR   GO; GO:0072308; P:negative regulation of metanephric nephron tubule epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0002230; P:positive regulation of defense response to virus by host; IMP:UniProtKB.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; IDA:UniProtKB.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:UniProtKB.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0007221; P:positive regulation of transcription of Notch receptor target; TAS:Reactome.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0007259; P:receptor signaling pathway via JAK-STAT; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0060334; P:regulation of interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:GOC.
DR   GO; GO:0061326; P:renal tubule development; IMP:UniProtKB.
DR   GO; GO:0051591; P:response to cAMP; ISS:UniProtKB.
DR   GO; GO:0034097; P:response to cytokine; ISS:UniProtKB.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0035456; P:response to interferon-beta; IMP:UniProtKB.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0043434; P:response to peptide hormone; ISS:UniProtKB.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060337; P:type I interferon signaling pathway; IDA:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd10372; SH2_STAT1; 1.
DR   DisProt; DP00962; -.
DR   Gene3D; 1.10.532.10; -; 1.
DR   Gene3D; 1.10.8.1200; -; 1.
DR   Gene3D; 2.60.40.630; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR001217; STAT.
DR   InterPro; IPR038295; STAT1_C_sf.
DR   InterPro; IPR035859; STAT1_SH2.
DR   InterPro; IPR022752; STAT1_TAZ2-bd_C.
DR   InterPro; IPR036535; STAT_N_sf.
DR   InterPro; IPR013800; STAT_TF_alpha.
DR   InterPro; IPR015988; STAT_TF_coiled-coil.
DR   InterPro; IPR013801; STAT_TF_DNA-bd.
DR   InterPro; IPR012345; STAT_TF_DNA-bd_N.
DR   InterPro; IPR013799; STAT_TF_prot_interaction.
DR   PANTHER; PTHR11801; PTHR11801; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF12162; STAT1_TAZ2bind; 1.
DR   Pfam; PF01017; STAT_alpha; 1.
DR   Pfam; PF02864; STAT_bind; 1.
DR   Pfam; PF02865; STAT_int; 1.
DR   SMART; SM00964; STAT_int; 1.
DR   SUPFAM; SSF47655; SSF47655; 1.
DR   SUPFAM; SSF48092; SSF48092; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; ADP-ribosylation;
KW   Alternative splicing; Antiviral defense; Coiled coil; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; DNA-binding;
KW   Host-virus interaction; Isopeptide bond; Methylation; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; SH2 domain;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:22223895"
FT   CHAIN           2..750
FT                   /note="Signal transducer and activator of transcription 1-
FT                   alpha/beta"
FT                   /id="PRO_0000182410"
FT   DOMAIN          573..670
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   COILED          136..317
FT                   /evidence="ECO:0000269|PubMed:9630226"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000244|PubMed:22223895"
FT   MOD_RES         114
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MOD_RES         175
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MOD_RES         296
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MOD_RES         366
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MOD_RES         525
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MOD_RES         637
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MOD_RES         657
FT                   /note="ADP-ribosyl glutamic acid; by PARP14"
FT                   /evidence="ECO:0000269|PubMed:27796300"
FT   MOD_RES         665
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MOD_RES         701
FT                   /note="Phosphotyrosine; by JAK1, JAK2 or TYK2"
FT                   /evidence="ECO:0000269|PubMed:17561467,
FT                   ECO:0000269|PubMed:19088846, ECO:0000269|PubMed:21135090,
FT                   ECO:0000269|PubMed:22065572, ECO:0000269|PubMed:26479788,
FT                   ECO:0000269|PubMed:27796300, ECO:0000269|PubMed:28753426,
FT                   ECO:0000269|PubMed:7657660"
FT   MOD_RES         705
FT                   /note="ADP-ribosyl glutamic acid; by PARP14"
FT                   /evidence="ECO:0000269|PubMed:27796300"
FT   MOD_RES         708
FT                   /note="Phosphoserine; by IKKE"
FT                   /evidence="ECO:0000269|PubMed:22065572"
FT   MOD_RES         727
FT                   /note="Phosphoserine; by MAPK14"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:18691976, ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163,
FT                   ECO:0000269|PubMed:15322115, ECO:0000269|PubMed:17897103,
FT                   ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:22065572,
FT                   ECO:0000269|PubMed:26479788, ECO:0000269|PubMed:7543024"
FT   MOD_RES         745
FT                   /note="Phosphoserine; by IKKE"
FT                   /evidence="ECO:0000250|UniProtKB:P42225"
FT   CROSSLNK        703
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000244|PubMed:25114211"
FT   CROSSLNK        703
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         713..750
FT                   /note="Missing (in isoform Beta)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.6"
FT                   /id="VSP_006282"
FT   VARIANT         30
FT                   /note="I -> T (in dbSNP:rs34255470)"
FT                   /id="VAR_034521"
FT   VARIANT         165
FT                   /note="D -> G (in IMD31C; gain of function mutation
FT                   associated with increased STAT1 phosphorylation due to
FT                   impaired nuclear dephosphorylation; dbSNP:rs387906764)"
FT                   /evidence="ECO:0000269|PubMed:21727188,
FT                   ECO:0000269|PubMed:23709754"
FT                   /id="VAR_065934"
FT   VARIANT         165
FT                   /note="D -> H (in IMD31C; dbSNP:rs387906767)"
FT                   /evidence="ECO:0000269|PubMed:21727188"
FT                   /id="VAR_065935"
FT   VARIANT         170
FT                   /note="Y -> N (in IMD31C; dbSNP:rs387906766)"
FT                   /evidence="ECO:0000269|PubMed:21727188"
FT                   /id="VAR_065936"
FT   VARIANT         174
FT                   /note="C -> R (in IMD31C; dbSNP:rs387906763)"
FT                   /evidence="ECO:0000269|PubMed:21727188"
FT                   /id="VAR_065937"
FT   VARIANT         179
FT                   /note="N -> K (in IMD31C; gain of function; increases
FT                   transactivation activity in response to IFNG;
FT                   dbSNP:rs587777628)"
FT                   /evidence="ECO:0000269|PubMed:23709754"
FT                   /id="VAR_075494"
FT   VARIANT         201
FT                   /note="K -> N (in IMD31B; not deleterious in terms of most
FT                   STAT1 functions; causes abnormal splicing out of exon 8
FT                   from most mRNAs thereby decreasing protein levels by
FT                   approximately 70%; dbSNP:rs587776870)"
FT                   /evidence="ECO:0000269|PubMed:20841510"
FT                   /id="VAR_065815"
FT   VARIANT         202
FT                   /note="M -> I (in IMD31C)"
FT                   /evidence="ECO:0000269|PubMed:21727188"
FT                   /id="VAR_065938"
FT   VARIANT         202
FT                   /note="M -> V (in IMD31C; dbSNP:rs387906762)"
FT                   /evidence="ECO:0000269|PubMed:21727188"
FT                   /id="VAR_065939"
FT   VARIANT         267
FT                   /note="A -> V (in IMD31C; dbSNP:rs387906759)"
FT                   /evidence="ECO:0000269|PubMed:21714643,
FT                   ECO:0000269|PubMed:21727188"
FT                   /id="VAR_065940"
FT   VARIANT         271
FT                   /note="Q -> P (in IMD31C; dbSNP:rs387906768)"
FT                   /evidence="ECO:0000269|PubMed:21727188"
FT                   /id="VAR_065941"
FT   VARIANT         274
FT                   /note="R -> Q (in IMD31C; gain of function; increases STAT1
FT                   phosphorylation due to impaired nuclear dephosphorylation;
FT                   increases transactivation activity in response to IFNG;
FT                   dbSNP:rs387906760)"
FT                   /evidence="ECO:0000269|PubMed:21727188,
FT                   ECO:0000269|PubMed:23709754"
FT                   /id="VAR_065942"
FT   VARIANT         274
FT                   /note="R -> W (in IMD31C; gain of function; increases
FT                   phosphorylation in response to IFNG, IFNA and IL27 due to a
FT                   loss of dephosphorylation; dbSNP:rs387906758)"
FT                   /evidence="ECO:0000269|PubMed:21714643,
FT                   ECO:0000269|PubMed:21727188, ECO:0000269|PubMed:23709754"
FT                   /id="VAR_065943"
FT   VARIANT         278
FT                   /note="K -> E (in IMD31C; gain of function; increases
FT                   phosphorylation in response to IFNG and IFNA due to a loss
FT                   of dephosphorylation; dbSNP:rs863223398)"
FT                   /evidence="ECO:0000269|PubMed:25288569"
FT                   /id="VAR_075495"
FT   VARIANT         285
FT                   /note="Q -> R (in IMD31C; gain of function; increases
FT                   transactivation activity in response to IFNG;
FT                   dbSNP:rs587777629)"
FT                   /evidence="ECO:0000269|PubMed:23709754"
FT                   /id="VAR_075496"
FT   VARIANT         286
FT                   /note="K -> I (in IMD31C; dbSNP:rs387906761)"
FT                   /evidence="ECO:0000269|PubMed:21727188"
FT                   /id="VAR_065944"
FT   VARIANT         288
FT                   /note="T -> A (in IMD31C; dbSNP:rs387906765)"
FT                   /evidence="ECO:0000269|PubMed:21727188"
FT                   /id="VAR_065945"
FT   VARIANT         298
FT                   /note="K -> N (in IMD31C; gain of function; increases basal
FT                   STAT1 phosphorylation levels which are 10-20 fold higher
FT                   than controls after IFNG stimulation)"
FT                   /evidence="ECO:0000269|PubMed:26514428"
FT                   /id="VAR_075497"
FT   VARIANT         320
FT                   /note="E -> Q (in IMD31A; affects the DNA-binding activity
FT                   of the protein; dbSNP:rs137852680)"
FT                   /evidence="ECO:0000269|PubMed:16934001"
FT                   /id="VAR_065816"
FT   VARIANT         384
FT                   /note="G -> D (in IMD31C; gain of function; increases
FT                   phosphorylation in response to IFNG and IFNA due to a loss
FT                   of dephosphorylation; dbSNP:rs796065052)"
FT                   /evidence="ECO:0000269|PubMed:25288569"
FT                   /id="VAR_075498"
FT   VARIANT         385
FT                   /note="T -> M (in IMD31C; gain of function; increases
FT                   phosphorylation in response to IFNG, IFNA and IL27 due to a
FT                   loss of dephosphorylation; dbSNP:rs587777630)"
FT                   /evidence="ECO:0000269|PubMed:23709754,
FT                   ECO:0000269|PubMed:25288569"
FT                   /id="VAR_075499"
FT   VARIANT         463
FT                   /note="Q -> H (in IMD31A; affects the DNA-binding activity
FT                   of the protein; dbSNP:rs137852679)"
FT                   /evidence="ECO:0000269|PubMed:16934001"
FT                   /id="VAR_065817"
FT   VARIANT         491
FT                   /note="P -> A (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036001"
FT   VARIANT         600
FT                   /note="L -> P (in IMD31B; found in an infant who died of a
FT                   viral-like illness associated with complete STAT1
FT                   deficiency; dbSNP:rs137852678)"
FT                   /evidence="ECO:0000269|PubMed:12590259"
FT                   /id="VAR_018265"
FT   VARIANT         637
FT                   /note="K -> E (in IMD31A; affects both phosphorylation and
FT                   DNA-binding activity; results in impaired STAT1-mediated
FT                   cellular response to IFN-gamma and interleukin-27;
FT                   dbSNP:rs587777705)"
FT                   /evidence="ECO:0000269|PubMed:22573496"
FT                   /id="VAR_068713"
FT   VARIANT         673
FT                   /note="K -> R (in IMD31A; impairs tyrosine phosphorylation;
FT                   results in impaired STAT1-mediated cellular response to
FT                   IFN-gamma and interleukin-27; dbSNP:rs587777704)"
FT                   /evidence="ECO:0000269|PubMed:22573496"
FT                   /id="VAR_068714"
FT   VARIANT         701
FT                   /note="Y -> C (in IMD31B; disrupts transactivation activity
FT                   in response to IFNG)"
FT                   /evidence="ECO:0000269|PubMed:23709754"
FT                   /id="VAR_075500"
FT   VARIANT         706
FT                   /note="L -> S (in IMD31A; loss of GAF and ISGF3 activation;
FT                   impairs the nuclear accumulation of GAF but not of ISGF3 in
FT                   heterozygous cells stimulated by IFNs; affects
FT                   phosphorylation of the protein; dbSNP:rs137852677)"
FT                   /evidence="ECO:0000269|PubMed:11452125,
FT                   ECO:0000269|PubMed:16934001"
FT                   /id="VAR_018266"
FT   MUTAGEN         110
FT                   /note="K->R: Sumoylated."
FT                   /evidence="ECO:0000269|PubMed:12764129"
FT   MUTAGEN         114
FT                   /note="K->A: No effect on IFN-alpha-induced STAT1
FT                   phosphorylation and nuclear translocation."
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MUTAGEN         175
FT                   /note="K->A: No effect on IFN-alpha-induced STAT1
FT                   phosphorylation and nuclear translocation."
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MUTAGEN         296
FT                   /note="K->A: No effect on IFN-alpha-induced STAT1
FT                   phosphorylation and nuclear translocation."
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MUTAGEN         366
FT                   /note="K->A: No effect on IFN-alpha-induced STAT1
FT                   phosphorylation and nuclear translocation."
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MUTAGEN         525
FT                   /note="K->A: Strongly reduced IFN-alpha-induced STAT1
FT                   phosphorylation and nuclear translocation. Does not affect
FT                   ability to homodimerize."
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MUTAGEN         636..637
FT                   /note="KK->AA: No effect on IFN-alpha-induced STAT1
FT                   phosphorylation and nuclear translocation."
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MUTAGEN         656..658
FT                   /note="AEN->CEC: Enhances STAT1 nuclear translocation and
FT                   interferon (IFN)-stimulated gene (ISG) expression in
FT                   response to IFN-beta stimulation. Reduces viral load in
FT                   infected cultured cells."
FT                   /evidence="ECO:0000269|PubMed:26479788"
FT   MUTAGEN         657
FT                   /note="E->Q: Loss of ADP-ribosylation and increased Tyr-701
FT                   phosphorylation; when associated with Q-705."
FT                   /evidence="ECO:0000269|PubMed:27796300"
FT   MUTAGEN         665
FT                   /note="K->A: No effect on IFN-alpha-induced STAT1
FT                   phosphorylation and nuclear translocation."
FT                   /evidence="ECO:0000269|PubMed:28753426"
FT   MUTAGEN         701
FT                   /note="Y->E: Not phosphorylated at S-708 upon IFNB
FT                   induction."
FT                   /evidence="ECO:0000269|PubMed:17897103,
FT                   ECO:0000269|PubMed:22065572"
FT   MUTAGEN         701
FT                   /note="Y->F: No effect on basal sumoylation. Enhances
FT                   sumoylation in the presence of MAPK stimulation.
FT                   Phosphorylated at S-708 upon IFNB induction."
FT                   /evidence="ECO:0000269|PubMed:17897103,
FT                   ECO:0000269|PubMed:22065572"
FT   MUTAGEN         703
FT                   /note="K->R: Abolishes sumoylation by SUMO1. Increased IFN-
FT                   gamma-mediated transactivation."
FT                   /evidence="ECO:0000269|PubMed:12764129,
FT                   ECO:0000269|PubMed:12855578"
FT   MUTAGEN         705
FT                   /note="E->Q: Loss of ADP-ribosylation and increased Tyr-701
FT                   phosphorylation; when associated with Q-657."
FT                   /evidence="ECO:0000269|PubMed:27796300"
FT   MUTAGEN         708
FT                   /note="S->A: Phosphorylated at Y-701 upon IFNB induction."
FT                   /evidence="ECO:0000269|PubMed:22065572"
FT   MUTAGEN         708
FT                   /note="S->D: Not phosphorylated at Y-701 upon IFNB
FT                   induction."
FT                   /evidence="ECO:0000269|PubMed:22065572"
FT   MUTAGEN         727
FT                   /note="S->A: Decreased transcriptional activation. No
FT                   effect on basal sumoylation. No enhancement of sumoylation
FT                   on MAPK stimulation. No PRKCD-induced apoptosis. Upon IFNB
FT                   induction, phosphorylated at Y-701 but not at S-708."
FT                   /evidence="ECO:0000269|PubMed:15322115,
FT                   ECO:0000269|PubMed:17897103, ECO:0000269|PubMed:22065572"
FT   MUTAGEN         727
FT                   /note="S->D: No change in enhancement of MAPK-induced
FT                   sumoylation. Basal interaction with PIAS1. Interaction with
FT                   PIAS1 increased on MAPK stimulation."
FT                   /evidence="ECO:0000269|PubMed:15322115,
FT                   ECO:0000269|PubMed:17897103, ECO:0000269|PubMed:22065572"
FT   MUTAGEN         727
FT                   /note="S->E: No change in enhancement of MAPK-induced
FT                   sumoylation."
FT                   /evidence="ECO:0000269|PubMed:15322115,
FT                   ECO:0000269|PubMed:17897103, ECO:0000269|PubMed:22065572"
FT   CONFLICT        46
FT                   /note="A -> T (in Ref. 2; ADA59516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        307
FT                   /note="S -> G (in Ref. 4; BAF85293)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        718
FT                   /note="Q -> R (in Ref. 5; CAH18430)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..7
FT                   /evidence="ECO:0000244|PDB:3WWT"
FT   HELIX           12..21
FT                   /evidence="ECO:0000244|PDB:3WWT"
FT   STRAND          23..26
FT                   /evidence="ECO:0000244|PDB:3WWT"
FT   HELIX           28..33
FT                   /evidence="ECO:0000244|PDB:3WWT"
FT   HELIX           35..40
FT                   /evidence="ECO:0000244|PDB:3WWT"
FT   HELIX           43..46
FT                   /evidence="ECO:0000244|PDB:3WWT"
FT   HELIX           50..73
FT                   /evidence="ECO:0000244|PDB:3WWT"
FT   HELIX           77..94
FT                   /evidence="ECO:0000244|PDB:3WWT"
FT   HELIX           99..120
FT                   /evidence="ECO:0000244|PDB:3WWT"
FT   HELIX           121..125
FT                   /evidence="ECO:0000244|PDB:1YVL"
FT   HELIX           137..179
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           189..192
FT                   /evidence="ECO:0000244|PDB:1YVL"
FT   HELIX           193..195
FT                   /evidence="ECO:0000244|PDB:1YVL"
FT   HELIX           198..247
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           257..286
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           293..316
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          317..321
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          334..336
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          339..347
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           352..354
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   TURN            355..357
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          359..365
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           370..373
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          374..376
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          380..382
FT                   /evidence="ECO:0000244|PDB:1YVL"
FT   STRAND          386..389
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          391..395
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   TURN            396..398
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          399..408
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          421..425
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          433..441
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          444..451
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          455..460
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           461..463
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           464..477
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           486..488
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           495..509
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           516..526
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           539..543
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          550..552
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           554..568
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           570..574
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           584..590
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   TURN            591..593
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          601..603
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          612..616
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          621..624
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          627..631
FT                   /evidence="ECO:0000244|PDB:1YVL"
FT   HELIX           636..640
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           644..649
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   STRAND          657..659
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           673..677
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   TURN            678..680
FT                   /evidence="ECO:0000244|PDB:1BF5"
FT   HELIX           728..738
FT                   /evidence="ECO:0000244|PDB:2KA6"
FT   TURN            739..742
FT                   /evidence="ECO:0000244|PDB:2KA6"
FT   HELIX           743..745
FT                   /evidence="ECO:0000244|PDB:2KA6"
FT   TURN            746..748
FT                   /evidence="ECO:0000244|PDB:2KA6"
SQ   SEQUENCE   750 AA;  87335 MW;  054A813522364BA6 CRC64;
     MSQWYELQQL DSKFLEQVHQ LYDDSFPMEI RQYLAQWLEK QDWEHAANDV SFATIRFHDL
     LSQLDDQYSR FSLENNFLLQ HNIRKSKRNL QDNFQEDPIQ MSMIIYSCLK EERKILENAQ
     RFNQAQSGNI QSTVMLDKQK ELDSKVRNVK DKVMCIEHEI KSLEDLQDEY DFKCKTLQNR
     EHETNGVAKS DQKQEQLLLK KMYLMLDNKR KEVVHKIIEL LNVTELTQNA LINDELVEWK
     RRQQSACIGG PPNACLDQLQ NWFTIVAESL QQVRQQLKKL EELEQKYTYE HDPITKNKQV
     LWDRTFSLFQ QLIQSSFVVE RQPCMPTHPQ RPLVLKTGVQ FTVKLRLLVK LQELNYNLKV
     KVLFDKDVNE RNTVKGFRKF NILGTHTKVM NMEESTNGSL AAEFRHLQLK EQKNAGTRTN
     EGPLIVTEEL HSLSFETQLC QPGLVIDLET TSLPVVVISN VSQLPSGWAS ILWYNMLVAE
     PRNLSFFLTP PCARWAQLSE VLSWQFSSVT KRGLNVDQLN MLGEKLLGPN ASPDGLIPWT
     RFCKENINDK NFPFWLWIES ILELIKKHLL PLWNDGCIMG FISKERERAL LKDQQPGTFL
     LRFSESSREG AITFTWVERS QNGGEPDFHA VEPYTKKELS AVTFPDIIRN YKVMAAENIP
     ENPLKYLYPN IDKDHAFGKY YSRPKEAPEP MELDGPKGTG YIKTELISVS EVHPSRLQTT
     DNLLPMSPEE FDEVSRIVGS VEFDSMMNTV
//
